Renovion is a clinical stage pharmaceutical company focused on developing ARINA-1, a novel nebulized therapy delivered to the lungs to treat pulmonary diseases. ARINA-1 clears mucus and reduces damaging inflammation in the airways to restore lung health.
Renovion is starting clinical trials in non-CF bronchiectasis, lung transplant, and NTM pulmonary disease in 2022.
Renovion is starting clinical trials in non-CF bronchiectasis, lung transplant, and NTM pulmonary disease in 2022.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
ARINA-1
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
